- Unique PARP/Tankyrase inhibitor
- DRP® : Gene Expression Based Biomarker For Predicting Response To Cancer Therapy
Thomas Jensen, CEO
May 2025
NASDAQ: ALLR
Nasdaq: ALLR
Copyright © 2023 Allarity Therapeutics. All rights reserved.
Our DRP® Companion Diagnostics Platform
The DRP® Platform Addresses the Complexity of Cancer
Cancer is Very Complex"Systems biology" is used to analyze all genes (~25,000) expressed in a cancer cell/tumor, without bias towards current knowledge of relevant drug targets or pathways.
The Tumor Tells us What is ImportantInput is generated by taking drug testing data from cancer cell lines. Our DRP® engine then applies the system biology analysis as a "filter" of human tumor biopsy data, to yield a 50 to 400 gene DRP® signature for that specific drug.
Graph of all 680 non-redundant proteins
In vitro TRANSCRIPT
-OMICS
HUM AN SYSTEM S BIOLOGY
In vitro Drug Response
DATA
DRP® CDx: Predicting a Cancer Patient's Drug Response
WEAK
WEAK
MODERATE
STRONG
STRONG
Step 1 Step 2 Step 3
Patients' biopsy samples
PATIENTS' TUMORS
Compare patients' tumor gene
expression to DRP® signature
PATIENTS' TUMORS
Identify patients with high DRP® score for a given drug
DRP +
| Attention: This is an excerpt of the original content. To continue reading it, access the original document here. |